- Сучасні маркери прогнозування прееклампсії
Сучасні маркери прогнозування прееклампсії
HEALTH OF WOMAN. 2019.10(146): 77–91; doi 10.15574/HW.2019.146.77
Романенко Т. Г., Суліменко О. М.
Національна медична академія післядипломної освіти імені П.Л. Шупика МОЗ України, м. Київ
Гіпертензивні розлади під час вагітності є однією з основних причин материнської і перинатальної захворюваності і смертності в усьому світі. Разом з передчасним відшаруванням плаценти, затримкою росту плода і невиношуванням вагітності прееклампсія належать до «великих акушерських синдромів» (Great Obstetrical Syndromes), пов’язаних з патологією плацентації. Понад 75% материнської смертності припадає на чотири причини: прееклампсія, сепсис, кровотечі і екстрагенітальні захворювання. Згідно з ВООЗ, тяжка прееклампсія ускладнює від 2 до 8% всіх вагітностей і в структурі прямих причин материнської смертності, як і раніше, посідає 2-е місце і становить близько 14%. Прееклампсія залишається однією з основних причин захворюваності новонароджених (640–780‰) та перинатальної смертності (18–30‰).
Пошуки клініко-діагностичних маркерів, які б дали можливість з високою ймовірністю та специфічністю визначити термін виникнення прееклампсії, тривають. Жоден з відомих сьогодні маркерів поодинці не здатен достовірно прогнозувати розвиток прееклампсії. Прогностична модель – це альтернативна основа для клінічної практики, що дає можливість для прогнозування результатів і вчасного прийняття рішень щодо їхнього поліпшення.
Проведено огляд практичних рекомендацій основних світових профільних організацій щодо використання прогностичних моделей. Досліджено позицію ключових профільних організацій з питання прогнозування прееклампсії на сучасному етапі та залучення у цьому прогностичних моделей. Зібрано дані проведених досліджень щодо використання біохімічних маркерів та їхніх комбінацій у прогнозуванні розвитку прееклампсії. Вивчено найбільш перспективні прогностичні моделі, у яких використовують анамнестичні, інструментальні дані та результати біохімічних маркерів. Наведено прогностичну цінність та специфічність цих моделей для визначення ранньої та пізньої маніфестації прееклампсії, а також можливого їхнього впровадження у клінічну практику.
Ключові слова: прееклампсія, прогнозування, вагітність, материнська смертність, гіпертензія, біохімічні маркери.
СПИСОК ЛІТЕРАТУРИ
1. Ozimek JA, Eddins RM, Greene N, Karagyozyan D, Pak S, Wong M. Opportunities for improvement in care among women with severe maternal morbidity. Am J Obstet Gynecol. 2016;215:509.e 501–506. https://doi.org/10.1016/j.ajog.2016.05.022; PMid:27210068
2. Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction and diagnosis of placental dysfunction: an approach for clinical integration / I. Herraiz [et al.]. // Int. J. Mol. Sci.– 2015.–Vol. 16, N 8.– P. 19009-19026. https://doi.org/10.3390/ijms160819009 PMid:26287164 PMCid:PMC4581283
3. Friedman, A.M. Prediction and prevention of ischemic placental disease / A.M. Friedman, K.L. Cleary // Semin. Perinatol.– 2014.– Vol. 38, N 3.– P. 177-182. https://doi.org/10.1053/j.semperi.2014.03.002; PMid:24836830
4. Williams Obstetrics, 24th ed. / F. Cunningham [et al.]. – New-York: McGraw-Hill, 2014.
5. Александрова, А.А.Геномные и постгеномные маркеры развития плаценты и плода/ А.А. Александрова, Л.В. Гутникова, Е.Г. Деревянчук. – Ростовн/Д: ЮФУ, 2011.– С. 46-48.
6. Elective delivery at 340(/)7 to 366(/)7 weeks’ gestation and its impact on neonatal outcomes in women with stable mild gestational hypertension / J.R. Barton[et al.] // Am. J. Obstet. Gynecol.– 2011.– Vol. 204, N 1.– P. 44-45. https://doi.org/10.1016/j.ajog.2010.08.030; PMid:20934682
7. Abalos E., Cuesta C., Carroli G., Qureshi Z., Widmer M., Vogel J., Souza J. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization multicountry survey on maternal and newborn health // BJOG : an international journal of obstetrics and gynecology. 2014. №121. Р.14–24. https://doi.org/10.1111/1471-0528.12629; PMid:24641531
8. Scott H., Danel I. Accountability for improving maternal and newborn health // Best Practice & Research Clinical Obstetrics & Gynaecology. 2016. №36. Р.45–56. https://doi.org/10.1016/j.bpobgyn.2016.05.009; PMid:27473405
9. Abstracts of the XXII FIGO World Congress of Gynecology & Obstetrics. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 3:43-991. https://doi.org/10.1002/ijgo.12584; PMid:30306572
10. Наказ №676 МОЗ України від 31.12.2004 р. «Про затвердження клінічних протоколів з акушерської та гінекологічної допомоги в Україні «Гіпертензивні розлади під час вагітності» 2004.
11. ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. Obstet Gynecol. 2018 Jul;132(1):e44-e52. https://doi.org/10.1097/AOG.0000000000002708; PMid:29939940
12. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach.. J Hum Hypertens. 2010 Feb;24(2):104-10. https://doi.org/10.1038/jhh.2009.45; PMid:19516271
13. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy.–London: RCOG Press, 2010
14. ACOG. First-trimester risk assessment for early-onset preeclampsia // Obstetrics and Gynecology.–2015.– Vol. 126.–Р.25-27. https://doi.org/10.1097/AOG.0000000000001049; PMid:26287789
15. Multicenters creening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison to NICE guidelines and ACOG recommendations / O’Gorman [et al.] // Ultrasound Obstet Gynecol.–2017.– Vol. 49.– P. 756-760. https://doi.org/10.1002/uog.17455; PMid:28295782
16. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001; 20(1):IX-XIV. https://doi.org/10.3109/10641950109152635; PMid:12044323
17. Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to preeclampsia and fetal growth retardation. BJOG 1981; 88: 876– 881. https://doi.org/10.1111/j.1471-0528.1981.tb02222.x; PMid:7272259
18. Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet 2010;376(9741):631–44. https://doi.org/10.1016/S0140-6736(10)60279-6
19. Wikström A-K, Larsson A, Eriksson UJ, Nash P, NordénLindeberg S, Olovsson M./ Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007.,109(6):1368–1374. https://doi.org/10.1097/01.AOG.0000264552.85436.a1; PMid:17540809
20. Bauman A. The epidemiology of clinical tests. Aust Prescr. 1990;13:62-4. https://doi.org/10.18773/austprescr.1990.001
21. The FIGO Textbook of Pregnancy Hypertension: an evidence-based guide to monitoring, prevention and management. Carlisle: The Global Library of Women’s Medicine/ Magee LA, (ed.), von Dadelszen P, (ed.), Stones W, (ed.), Mathai M, (ed.). 2016.
22. Šimundić AM. Measures of Diagnostic Accuracy: Basic Definitions. EJIFCC. 2009 Jan 20;19(4):203-11.
23. ESC Guidelines for the management of cardiovascular diseases during pregnancy. 2018 Sep 7;39(34):3165-3241.
24. Cunningham, F. Gary,, et al. Williams Obstetrics. 24th edition. New York: McGraw-Hill Education, 2014.
25. Gasse C, Côté M, Chaillet N, Giguère Y, Blanchet G, Tétu A, Bujold E, First-trimester mean arterial blood pressure to predict the risk of preeclampsia. Am. J. Obstet. Gynecol. 2017; 216 (1): S544–S545. https://doi.org/10.1016/j.ajog.2016.11.873
26. Gallo D, Poon L, Fernandez M, Wright D, Nicolaides K. Prediction of Preeclampsia by Mean Arterial Pressure at 11–13 and 20–24 Weeks’ Gestation. Fetal Diagn Ther. 2014;36(1):28–37. https://doi.org/10.1159/000360287; PMid:24752037
27. Gasse C, Boutin A, Coté M, Chaillet N, Bujold E, Demers S. First-trimester mean arterial blood pressure and the risk of preeclampsia: The Great Obstetrical Syndromes (GOS) study. Pregnancy Hypertens. 2018 Apr;12:178-182. https://doi.org/10.1016/j.preghy.2017.11.005; PMid:29175170
28. Angiogenic factors for the prediction of preeclampsia in high-risk women / T.A. Moore Simas [et al.] // Am. J. Obstet. Gynecol.– 2007.–Vol. 197, N 3.– P. 241-248. https://doi.org/10.1016/j.ajog.2007.06.030; PMid:17826405
29. Association of inflammatory cytokines, lipid peroxidation end products and nitric oxide with the clinical severity and fetal outcome in preeclampsia in Indian women / L.K. Harris [et al.] // Indian J. Clin. Biochem.– 2014.– Vol. 29, N 2.–Р. 139144. https://doi.org/10.1007/s12291-013-0320-5; PMid:24757293 PMCid:PMC3990799
30. Accuracy of mean arterial pressure and blood pressure measurements in predicting preeclampsia: Systematic review and meta-analysis / J.S. Cnossen [et al.] // BMJ.– 2008.–Vol. 336.– P. 1117-1120. https://doi.org/10.1136/bmj.39540.522049.BE; PMid:18480117 PMCid:PMC2386627
31. Cote A, von Dadelszen P, Moutquin J, Ardilouze J, Magee LA. Microalbuminuria and the Hypertensive Disorders of Pregnancy. Curr Hypertens Rev 2010; 6(1):8–19. https://doi.org/10.2174/157340210790231690
32. Hafner E, Metzenbauer M, Stümpflen I, Waldhör T, Philipp K. First trimester placental and myometrial blood perfusion measured by 3D power Doppler in normal and unfavourable outcome pregnancies. Placenta. 2010 Sep;31(9):756-63. https://doi.org/10.1016/j.placenta.2010.06.011; PMid:20633928
33. Caruso A, Caforio L, Testa AC et al. Chronic hypertension in pregnancy: color Doppler investigation of uterine arteries as a predictive test for superimposed preeclampsia and adverse perinatal outcome. Journal of Perinatal Medicine. 1996; 24 : (2)141-53. https://doi.org/10.1515/jpme.1996.24.2.141; PMid:8773940
34. Matevosyan NR. Predictive accuracy of the first trimester Doppler scan: a meta-study. Wien Med Wochenschr. 2015 May ; 165(9-10):199-209. https://doi.org/10.1007/s10354-015-0358-5; PMid:26077833
35. Crispi F, Llurba E, Domínguez C, Martín-Gallán P, Cabero L, Gratacós E. Predictive value of angiogenic factors and uterine artery Doppler for early-versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol. 2008 Mar;31(3):303-9. https://doi.org/10.1002/uog.5184; PMid:18058842
36. Bolin M, Wikström A, Wiberg-Itzel E, Olsson A, Ringvall M, Sundström-Poromaa I, et al. Prediction of Preeclampsia by Combining Serum Histidine-Rich Glycoprotein and Uterine Artery Doppler. Am J Hypertens. 2012;25(12):1305–1310. https://doi.org/10.1038/ajh.2012.112; PMid:22895448
37. Papageorghiou AT, Yu CKH, Cicero S, Bower S, Nicolaides KH. Second-trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 2002;12(2):78–88. https://doi.org/10.1080/jmf.12.2.78.88; PMid:12420836
38. Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks’ gestation. Obstet Gynecol. 2000 Oct;96(4):559-64. https://doi.org/10.1097/00006250-200010000-00015; PMid:11004359
39. García B, Llurba E, Valle L, Gómez-Roig MD, Juan M, Pérez-Matos C, Fernández M, García-Hernández JA, Alijotas-Reig J, Higueras MT, Calero I, Goya M, Pérez-Hoyos S, Carreras E, Cabero L. Do knowledge of uterine artery resistance in the second trimester and targeted surveillance improve maternal and perinatal outcome? UTOPIA study: a randomized controlled trial. Ultrasound Obstet Gynecol. 2016 Jun;47(6):680-9. https://doi.org/10.1002/uog.15873; PMid:26823208
40. Kleinrouweler CE, Bossuyt PMM, Thilaganathan B, Vollebregt KC, Arenas Ramírez J, Ohkuchi A, et al. Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis. Ultrasound Obstet Gynecol 2013;42(3):257–267. https://doi.org/10.1002/uog.12435; PMid:23417857
41. Caradeux J, Serra R, Nien J, Pérez-Sepulveda A, Schepeler M, Guerra F, et al. First trimester prediction of early onset preeclampsia using demographic, clinical, and sonographic data: a cohort study. 2013 Aug;33(8):732-6. https://doi.org/10.1002/pd.4113; PMid:23584890
42. Oliveira N, Magder LS, Blitzer MG, Baschat AA. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol. 2014;44(3):279–285. https://doi.org/10.1002/uog.13435; PMid:24913190
43. Goetzinger KR, Tuuli MG, Cahill AG, Macones GA, Odibo AO. Development and validation of a risk factor scoring system for first-trimester prediction of preeclampsia. Am J Perinatol. 2014 Dec;31(12):1049-56. https://doi.org/10.1055/s-0034-1371705; PMid:24705967 PMCid:PMC4185255
44. Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One. 2008 Jul 23;3(7):e2766. https://doi.org/10.1371/journal.pone.0002766; PMid:18648513 PMCid:PMC2447877
45. Мурашко А.В. Роль факторов роста в развитии плацентарной недостаточности и преэклампсии / А.В. Мурашко, Ш.М. Магомедова // Архив акушерства и гинекологии им. В.Ф. Снегирева. – 2015. – Т. 2, № 3. – С. 25-28.
46. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia/ C.J.Robinson, [et al.] //Am J Obstet Gynecol. 2006; 195 (1): 255-259. https://doi.org/10.1016/j.ajog.2005.12.049; PMid:16813756
47. Redman C.W. Placental Stress and Pre-eclampsia: A Revised View / C.W. Redman, I.L. Sargent // Placenta. 2009;Suppl A:S.38-42. https://doi.org/10.1016/j.placenta.2008.11.021; PMid:19138798
48. Robinson C.J.The splice variants of vascular endothelial growth factor (VEGF) and their receptors / C.J Robinson, S.E Stringer // J Cell Sci. 2001; Vol. 114; (Pt 5): 853-865.
49. Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger C, Burke O, Chan Y, Harding JE, Yockell-Lelièvre J, Hu Y, Chappell LC, Griffin MJ, Shennan AH, Magee LA, Gruslin A, von Dadelszen P. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016 Jun;42:1-8. https://doi.org/10.1016/j.placenta.2016.03.010; PMid:27238707
50. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350: 672–683. https://doi.org/10.1056/NEJMoa031884; PMid:14764923
51. Диагностическая значимость определения плацентарного фактора роста и растворимой FMS-подобной тирозинкиназы-1 в качестве маркеров преэклампсии / Т.Ю.Иванец [и др.] // Проблемы репродукции. – 2015. – Т. 21, № 4. – С. 129-133. https://doi.org/10.17116/repro2015214129-133
52. Роль ангиогенных факторов роста в патогенезе преэклампсии и плацентарной недостаточности / О.В.Макаров [и др.] // Акушерство и гинекология. – 2014. – № 12. – С. 64-70.
53. Poon L.C., Nicolaides K.H. «Early prediction of preeclampsia.» Obstetrics and Gynecology International (2014). https://doi.org/10.1155/2014/297397; PMid:25136369 PMCid:PMC4127237
54. Akolekar R., Syngelaki A., Poon L., Wright D., Nicolaides K.H. «Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.» Fetal Diagn Ther, 33(2013):8-15. https://doi.org/10.1159/000341264; PMid:22906914
55. Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study. J Obstet Gynaecol Res. 2013;39(5): 881–890. https://doi.org/10.1111/jog.12006; PMid:23496304
56. Honigberg MC, Cantonwine DE, Thomas AM, Lim KH, Parry SI, McElrath TF. Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. J Perinatol. 2016 Mar;36(3):172-7. https://doi.org/10.1038/jp.2015.170; PMid:26583938
57. Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy? Arch Gynecol Obstet. 2013; 287(5):865–873. https://doi.org/10.1007/s00404-012-2662-2; PMid:23224699
58. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013 Nov 5;128(19):2121-31. https://doi.org/10.1161/CIRCULATIONAHA.113.003215; PMid:24190934
59. Bian Z, Shixia C, Duan T. First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia. PLoS One. 2015;10(4):e0124684. Published 2015 Apr 23. https://doi.org/10.1371/journal.pone.0124684; PMid:25906026 PMCid:PMC4408038
60. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the screening for pregnancy endpoints (SCOPE) international cohort study. Hypertension. 2014;64(3):644–52. https://doi.org/10.1161/HYPERTENSIONAHA.114.03578; PMid:25122928
61. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 2015;35(2):183–91. https://doi.org/10.1002/pd.4519; PMid:25346181
62. Parra-Cordero M, Rodrigo R, Barja P, Bosco C, Rencoret G, Sepúlveda-Martinez A, Quezada S. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol. 2013 May;41(5):538-44. https://doi.org/10.1002/uog.12264; PMid:22807133
63. Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Serum placental growth factor as a predictor of early onset preeclampsia in overweight/obese pregnant women. J Am Soc Hypertens. 2013 Mar-Apr;7(2):137-48. https://doi.org/10.1016/j.jash.2012.12.006; PMid:23394804
64. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest. 2000 Apr;80(4):443-54. https://doi.org/10.1038/labinvest.3780050; PMid:10780661
65. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-58. https://doi.org/10.1172/JCI17189; PMid:12618519 PMCid:PMC151901
66. Maynard S.E. Angiogenic factors and preeclampsia / S.E.Maynard, S.A.Karumanchi // Semin Nephrol. 2011; 31(1):33-4. https://doi.org/10.1016/j.semnephrol.2010.10.004; PMid:21266263 PMCid:PMC3063446
67. Mutter W.P. Molecular mechanisms of preeclampsia / W.P. Mutter, S.A.Karumanchi // Microvas Res. 2008; 75 (1): 1-8. https://doi.org/10.1016/j.mvr.2007.04.009; PMid:17553534 PMCid:PMC2241748
68. Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatol. 2000 Feb;24(1):24-8. https://doi.org/10.1016/S0146-0005(00)80050-6
69. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191: 1240–1246. https://doi.org/10.1016/j.ajog.2004.03.004; PMid:15507947
70. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E; EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 2012 Jun;119(7):778-87. https://doi.org/10.1111/j.1471-0528.2012.03311.x; PMid:22433027
71. Ohkuchi A, Hirashima C, Takahashi K, Suzuki H, Matsubara S, Suzuki M. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertens Res. 2013 Dec;36(12):1073-80. https://doi.org/10.1038/hr.2013.95; PMid:23966056
72. Аверкиева, В.С. Инновационные биомаркеры для диагностики и прогноза преэклампсии / В.С. Аверкиева, М.В. Лисянская // Лаборатория ЛПУ. Спецвыпуск.– 2016.– № 8.– С. 20-23.
73. Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet. 2015;292:507-18. https://doi.org/10.1007/s00404-015-3671-8; PMid:25716670
74. Engels T, Pape J, Schoofs K, Henrich W, Verlohren S. Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. Hypertens Pregnancy. 2013 Nov;32(4):459-73. https://doi.org/10.3109/10641955.2013.827205; PMid:23957293
75. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911-9. https://doi.org/10.1161/CIRCULATIONAHA.111.054361; PMid:22261192 PMCid:PMC3319742
76. Rana S, Schnettler WT, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013;32:189-201. https://doi.org/10.3109/10641955.2013.784788; PMid:23725084 PMCid:PMC3744824
77. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients / S. Verlohren [et al.] // Am. J. Obstet Gynecol.–2012.– Vol. 206, N 1. – P. 58. e1-8. https://doi.org/10.1016/j.ajog.2011.07.037; PMid:22000672
78. Hund M, Allegranza D, Schoedl M, Dilba P, Verhagen-Kamerbeek W, Stepan H. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregnancy Childbirth. 2014;14:324. https://doi.org/10.1186/1471-2393-14-324; PMid:25230734 PMCid:PMC4262142
79. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstro¨m M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13–22. https://doi.org/10.1056/NEJMoa1414838; PMid:26735990
80. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion / H. Stepan [et al.] // Am. J. Obstet. Gynecol.– 2008.– Vol. 198, N 2.– P.175-176. https://doi.org/10.1016/j.ajog.2007.08.052; PMid:18226617
81. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of preeclampsia / R. Akolekar [et al.] // Ultrasound Obstet. Gynecol.– 2008. – Vol. 32, N 6.– P. 732-739. https://doi.org/10.1002/uog.6244; PMid:18956425
82. Jim B, Karumanchi SA. Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. Semin Nephrol. 2017 Jul;37(4):386-397. https://doi.org/10.1016/j.semnephrol.2017.05.011; PMid:28711078
83. Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension. 2012; 59: 740-6. https://doi.org/10.1161/HYPERTENSIONAHA.111.181735; PMid:22311907
84. Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013;83:177-81. https://doi.org/10.1038/ki.2012.348; PMid:23014459
85. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011;108:1451-5. https://doi.org/10.1073/pnas.1011293108; PMid:21187414 PMCid:PMC3029692
86. Costantine MM, Cleary K, and Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric–Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013;121:349-53. https://doi.org/10.1097/AOG.0b013e31827d8ad5; PMid:23344286
87. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992 Sep 25;267(27):19027-30.
88. Мурашко, Л.Е. Оксид азота в генезе преэклампсии / Л.Е. Мурашко // Акушерство и гинекология. – 2009. – № 6. – С. 24-27.
89. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011 Jun 21;123(24):2856-69. https://doi.org/10.1161/CIRCULATIONAHA.109.853127; PMid:21690502 PMCid:PMC3148781
90. Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction / H. Nishizawa [et al.] // Reprod. Biol. Endocrinol.–2011.–Vol. 9.– P.107. https://doi.org/10.1186/1477-7827-9-107; PMid:21810232 PMCid:PMC3199758
91. Severe preeclampsia-related changes in gene expression at the maternalfetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin2 / V.D. Winn [et al.]// Endocrinology.–2009.– Vol. 150.– P. 452-462. https://doi.org/10.1210/en.2008-0990; PMid:18818296 PMCid:PMC2630905
92. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D’Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006 Jun;12(6):642-9. https://doi.org/10.1038/nm1429; PMid:16751767
93. Поздняков, И.М. Уровень лептина, про– и антивоспалительных цитокинов при беременности, осложненной различными формами артериальной гипертензии / И.М. Поздняков, А.В. Ширинская // Цитокины и воспаление. – 2015. – Т. 14, № 1. – С. 75-79.
94. Robinson C.J. Soluble endoglin as a second-trimester marker for preeclampsia / C.J. Robinson, D.D. Johnson // Am. J. Obstet. Gynecol. 2007; Vol. 197 (2), 174.e1-5. https://doi.org/10.1016/j.ajog.2007.03.058; PMid:17689640
95. Ngene NC, Moodley J. Role of angiogenic factors in the pathogenesis and management of pre-eclampsia. Int J Gynaecol Obstet. 2018 Apr;141(1):5-13. https://doi.org/10.1002/ijgo.12424; PMid:29222938
96. Cluver CA, Walker SP, Mol BW, Theron GB, Hall DR, Hiscock R, Hannan N, Tong S. Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. BMJ Open. 2015 Oct 28;5(10):e008211. https://doi.org/10.1136/bmjopen-2015-008211; PMid:26510725 PMCid:PMC4636658
97. Armaly Z, Jadaon JE, Jabbour A, Abassi ZA. Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches. Front Physiol. 2018;9:973. https://doi.org/10.3389/fphys.2018.00973; PMid:30090069 PMCid:PMC6068263
98. Saleh L, Samantar R, Garrelds IM, van den Meiracker AH, Visser W, Danser AHJ. Low Soluble Fms-Like Tyrosine Kinase-1, Endoglin, and Endothelin-1 Levels in Women With Confirmed or Suspected Preeclampsia Using Proton Pump Inhibitors. Hypertension. 2017 Sep;70(3):594-600. https://doi.org/10.1161/HYPERTENSIONAHA.117.09741; PMid:28716993
99. Karumanchi SA. Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy. Hypertension. 2016 Jun;67(6):1072-9. https://doi.org/10.1161/HYPERTENSIONAHA.116.06421; PMid:27067718
100. Характер изменений маркеров ангиогенеза. при гестозе / И.С. Сидорова [и др.] // Журнал Акушерство и гинекология.– 2009.– №3.– С. 38.
101. Celik, H. Vascular endothelial growth factor and endothelin-1 levels in normal pregnant women and pregnant women with pre-eclampsia / H. Celik, B. Avci, Y. Isik// J. Obstet. Gynaecol.– 2013.– Vol. 33.– P. 355-358. https://doi.org/10.3109/01443615.2013.769944; PMid:23654314
102. Biomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study / S. Masoura [et al.] // Eur. J. Obstet. Gynecol. Reprod. Biol.– 2014.– Vol. 175.– P.119-123. https://doi.org/10.1016/j.ejogrb.2014.01.012; PMid:24485669
103. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications / X. Fan [et al.] // J. Clin. Invest.– 2014.– Vol. 124.– P. 4941-4952. https://doi.org/10.1172/JCI76864; PMid:25329693 PMCid:PMC4347223
104. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One 2014;9(12):e113715. https://doi.org/10.1371/journal.pone.0113715; PMid:25436639 PMCid:PMC4249974
105. Zhang YG, Yang HL, Zhang YP, Ma QL, Long Y, Zheng ZX. Pigment epithelium-derived factor/vascular endothelial growth factor ratio for early prediction of preeclampsia: A prospective multicenter study in China. Pregnancy Hypertens. 2018 Oct;14:43-48. https://doi.org/10.1016/j.preghy.2018.07.005; PMid:30527117
106. Wong MK, Shawky SA, Aryasomayajula A, Green MA, Ewart T, Selvaganapathy PR, Raha S. Extracellular matrix surface regulates self-assembly of three-dimensional placental trophoblast spheroids. PLoS One. 2018 Jun 25;13(6):e0199632. https://doi.org/10.1371/journal.pone.0199632; PMid:29940046 PMCid:PMC6016924
107. Матриксные металлопротеиназы, их роль в физиологических и патологических процессах (обзор) / Л.Н. Рогова, Н.В. Шестернина, Т.В. Замечник, И.А. Фастова// Вестник новых медицинских технологий.– 2011.– Т. 18, №. 2.– С. 86-89.
108. Lоw 2-mеthохyеstrаdiоl lеvеls аt thе first trimеstеr оf рrеgnаnсy аrеаssосiаtеd with thе dеvеlорmеnt оf рrеесlаmрsiа/ A. Рrеz-Sерlvеdа [еt аl.] // Рrеnаt. Diаgn.– 2012.– Vol. 32, N 11.–Р.1053-1058.
109. Li W, Mata KM, Mazzuca MQ, Khalil RA. Altered matrix metalloproteinase-2 and-9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochemical pharmacology. 2014; 89(3):370–385. https://doi.org/10.1016/j.bcp.2014.03.017; PMid:24704473 PMCid:PMC4034157
110. Espino Y Sosa S, Flores-Pliego A, Espejel-Nuñez A, Medina-Bastidas D, Vadillo-Ortega F, Zaga-Clavellina V, Estrada-Gutierrez G. New Insights into the Role of Matrix Metalloproteinases in Preeclampsia. Int J Mol Sci. 2017 Jul 20;18(7). https://doi.org/10.3390/ijms18071448; PMid:28726716 PMCid:PMC5535939
111. Овчарова, В.С Молекулярные механизмы этиопатогенеза преэклампсии / В.С. Овчарова // ЭНИ Забайкальский медицинский вестник. – 2016– №4. –С.129-134.
112. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801. https://doi.org/10.1038/nrm3904; PMid:25415508 PMCid:PMC4316204
113. Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H, Suzuki Y, Li YF, Takayama M. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta. 2003 Jan;24(1):53-64. https://doi.org/10.1053/plac.2002.0867; PMid:12495660
114. Plaks V, Rinkenberger J, Dai J, Flannery M, Sund M, Kanasaki K, Ni W, Kalluri R, Werb Z. Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27). https://doi.org/10.1073/pnas.1309561110; PMid:23776237 PMCid:PMC3704020
115. Palei AC, Granger JP, Tanus-Santos JE. Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets. 2013 Mar;14(3):325-34. https://doi.org/10.2174/1389450111314030004; PMid:23316964
116. Chen J, Khalil RA. Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. Prog Mol Biol Transl Sci. 2017;148:87-165. https://doi.org/10.1016/bs.pmbts.2017.04.001; PMid:28662830 PMCid:PMC5548443
117. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy / A.C. Palei [et al.] // Exp. Mol. Pathol.– 2012.– Vol. 92.– P. 217-221. https://doi.org/10.1016/j.yexmp.2012.01.008; PMid:22327101
118. Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant / N.M. Eleuterio [et al.] // Pregnancy Hypertens.– 2015.– Vol.5.– P. 205-208. https://doi.org/10.1016/j.preghy.2015.03.001; PMid:25943646
119. Maternal serum levels of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in pregnancies with preeclampsia and those with a small for gestational age neonate: A longitudinal study / G. Karampas [et al.] // Prenat. Diagn.– 2014.– Vol. 34.– P. 726-733. https://doi.org/10.1002/pd.4337; PMid:24550181
120. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy / M. Montagnana [et al.] // J. Clin. Lab. Anal.– 2009.– Vol.23.– P. 88-92. https://doi.org/10.1002/jcla.20295; PMid:19288452 PMCid:PMC6649012
121. Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res. 2011;64:551–60. https://doi.org/10.1016/j.phrs.2011.05.005; PMid:21689755
122. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res. 2011;64:567–72. https://doi.org/10.1016/j.phrs.2011.04.002; PMid:21514386
123. Conde-Agudelo A, Bird S, Kennedy SH, Villar J, Papageorghiou AT. First– and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis. BJOG. 2015;122(1):41–55. 32. https://doi.org/10.1111/1471-0528.13096; PMid:25236870
124. Odibo AO. Pregnancy associated-plasma protein-a (PAPP-A) and alfa-fetoprotein (AFP) associated with placental abruption. Am J Obstet Gynecol. 2014;211(2):89–90. https://doi.org/10.1016/j.ajog.2014.03.062; PMid:24837457
125. Скрининг ранней преэклампсии в I триместре беременности на основе комбинированной оценки материнского сывороточного плацентарного фактора роста и допплерометрии маточных артерий / А.М. Холин [и др.] // Акушерство и гинекология. – 2015. – № 5. – С. 42-48.
126. Bilagi, A. Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study / A. Bilagi, D.L. Burke // Prenat Diagn.– 2017.– Vol. 37, N 7.– P. 705-711. https://doi.org/10.1002/pd.5069; PMid:28514830
127. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-А and pre-eclampsia. Ultrasound Obstet Gynecol. 2009;33(1):23–33. https://doi.org/10.1002/uog.6280; PMid:19090499
128. Schneuer F, Nassar N, Khambalia A, Tasevski V, Ashton A, Morris J, et al. First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review. Placenta. 2012;33(9): 735–740. https://doi.org/10.1016/j.placenta.2012.05.012; PMid:22748852
129. Lai J., Pinas A., Poon L.C., Agathokleous M., Nicolaides K.H. «Maternal serum placental growth factor, pregnancy-associated plasma protein A and free β-human chorionic gonadotrophin at 30–33 weeks in the prediction of pre-eclampsia.» Fetal Diagn Ther, 33(2013):164-72. https://doi.org/10.1159/000345090; PMid:23445908
130. Keikkala E, Vuorela P, Laivuori H, Romppanen J, Heinonen S, Stenman UH. First trimester hyperglycosylated human chorionic gonadotrophin in serum – a marker of early-onset preeclampsia. Placenta. 2013 Nov; 34(11):1059-65. https://doi.org/10.1016/j.placenta.2013.08.006; PMid:23993394
131. Kalkunte S, Navers T, Norris W, Banerjee P, Fazleabas A, Kuhn C, Jeschke U, Sharma S. Presence of non-functional hCG in preeclampsia and rescue of normal pregnancy by recombinant hCG. Placenta. 2010;31:A126
132. Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Brumatti LV, et al. First trimester maternal serum PIGF, free [beta]-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta. 2012;33(6):495. https://doi.org/10.1016/j.placenta.2012.03.003; PMid:22459245
133. Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn. 2009 Dec;29(12):1103-8. https://doi.org/10.1002/pd.2375; PMid:19777530
134. Nicolaides K.H. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound / K.H. Nicolaides, R. Bindra, O.M. Turan, // Ultrasound Obstet Gynecol. 2006; 27 (1): 13-17. https://doi.org/10.1002/uog.2686; PMid:16374755
135. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction / I. Chafetz, [et al.] // Am. J. Obstet. Gynecol. 2007; 197 (1): 35.e1-7.2. https://doi.org/10.1016/j.ajog.2007.02.025; PMid:17618748
136. L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with preeclampsia / A.M. Pimentel [et al.] // Hypertens. Res.– 2013. – Vol. 36, N 9.–Р.783-788. https://doi.org/10.1038/hr.2013.34; PMid:23575380
137. First trimester maternal serum placental protein 13 for the prediction of preeclampsia in women with a priori high risk / A. Khalil [et al.] // Prenat. Diagn.– 2009.– Vol. 29, N 8.– P. 781-789. https://doi.org/10.1002/pd.2287; PMid:19418482
138. Guibourdenche J, Handschuh K, Tsatsaris V, Gerbaud P, Leguy MC, Muller F, et al. Hyperglycosylated hCG is a marker of early human trophoblast invasion. J Clin Endocrinol Metab. 2010;95:E240–4. https://doi.org/10.1210/jc.2010-0138; PMid:20660042
139. Keikkala E, Koskinen S, Vuorela P, Laivuori H, Romppanen J, Heinonen S, Stenman UH. First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study. BMC Pregnancy Childbirth. 2016 Nov 25;16(1):378. https://doi.org/10.1186/s12884-016-1169-4; PMid:27887594 PMCid:PMC5124279
140. Keikkala E, Ranta JK, Vuorela P, Leinonen R, Laivuori H, Vaisanen S, et al. Serum hyperglycosylated human chorionic gonadotrophin at 14–17 weeks of gestation does not predict preeclampsia. Prenat Diagn. 2014;34:699–705. https://doi.org/10.1002/pd.4335; PMid:24464955
141. Nyren-Erickson EK, Jones JM, Srivastava DK, Mallik S. A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. Biochim Biophys Acta. 2013 Oct;1830(10):4445-55. https://doi.org/10.1016/j.bbagen.2013.05.011; PMid:23680494
142. Kuc S, Koster MP, Franx A, Schielen PC, Visser GH. Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia. PLoS One. 2013 May 22;8(5):e63546. https://doi.org/10.1371/journal.pone.0063546; PMid:23717445 PMCid:PMC3661579
143. Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG. 2010 Oct;117(11):1384-9. https://doi.org/10.1111/j.1471-0528.2010.02690.x; PMid:20840693
144. Cui L, Shu C, Liu Z, Tong W, Cui M, Wei C, Tang JJ, Liu X, Hai H, Jiang J, He J, Zhang DY, Ye F, Li Y. Serum protein marker panel for predicting preeclampsia. Pregnancy Hypertens. 2018 Oct;14:279-285. https://doi.org/10.1016/j.preghy.2018.01.009; PMid:29395656
145. Protocol for the prospective validation study: “Screening programme for pre-eclampsia” (SPREE) / M.Y. Tan [et al.] // Ultrasound Obstet Gynecol. – 2017. – Vol.50, N 2. – P. 175-179. https://doi.org/10.1002/uog.17467; PMid:28295773
146. Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66(8):497–506. https://doi.org/10.1097/OGX.0b013e3182331028; PMid:22018452
147. Costa Fda S, Murthi P, Keogh R, Woodrow N. Early screening for preeclampsia. Rev Bras Ginecol Obstet. 2011 Nov;33(11):367-75. https://doi.org/10.1590/S0100-72032011001100008; PMid:22267116
148. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton M, North RA, Paech M, Said JM. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015 Oct; 55(5):e1-29. https://doi.org/10.1111/ajo.12399; PMid:26412014
149. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010 Feb;24(2):104-10. https://doi.org/10.1038/jhh.2009.45; PMid:19516271
150. Lai J, Pinas A, Poon L, Agathokleous M, Nicolaides K. Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free beta-Human Chorionic Gonadotrophin at 30–33 Weeks in the Prediction of Pre-eclampsia. Fetal Diagn Ther 2013;33(3):164–172. https://doi.org/10.1159/000345090; PMid:23445908
151. Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, Hassan SS, Kim CJ, Chaiworapongsa T. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med. 2012;25(5):498–507. https://doi.org/10.3109/14767058.2011.591461; PMid:21867402 PMCid:PMC3401571
152. Myers J, Kenny L, McCowan L, Chan E, Dekker G, Poston L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG. 2013;120(10):1215–1223. https://doi.org/10.1111/1471-0528.12195; PMid:23906160
153. Bolin M, Wikström A, Wiberg-Itzel E, Olsson A, Ringvall M, Sundström-Poromaa I, et al. Prediction of Preeclampsia by Combining Serum Histidine-Rich Glycoprotein and Uterine Artery Doppler. Am JHypertens. 2012;25(12):1305–1310. https://doi.org/10.1038/ajh.2012.112; PMid:22895448
154. Park HJ, Kim SH, Jung YW, Shim SS, Kim JY, Cho YK, Farina A, Zanello M, Lee KJ, Cha DH. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childbirth. 2014 Jan 20;14:35. https://doi.org/10.1186/1471-2393-14-35; PMid:24444293 PMCid:PMC3944217
155. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11–13 weeks. Fetal Diagn Ther. 2013;33(1):16–27. https://doi.org/10.1159/000341712; PMid:22986844
156. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 2015;35(2):183–91. https://doi.org/10.1002/pd.4519; PMid:25346181
157. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol. 2008 Sep;199(3):266.e1-6. https://doi.org/10.1016/j.ajog.2008.06.069; PMid:18771978
158. Kuc S, Koster MP, Franx A, Schielen PC, Visser GH. Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia. PLoS One. 2013 May 22;8(5):e63546. https://doi.org/10.1371/journal.pone.0063546; PMid:23717445 PMCid:PMC3661579
159. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One 2014;9(12):e113715. https://doi.org/10.1371/journal.pone.0113715; PMid:25436639 PMCid:PMC4249974
160. Stepan H, Kuse-Föhl S, Klockenbusch W, et al. Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013). Geburtshilfe Frauenheilkd. 2015;75(9):900-914. https://doi.org/10.1055/s-0035-1557924; PMid:28435172 PMCid:PMC5396549
161. Queensland Maternity and Neonatal Clinical Guidelines Program (2010) Hypertensive disorders of pregnancy. Guideline No. MN10.13.V4-R15. Queensland health.
162. Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018 Sep 7;39(34):3165-3241.
163. National Institute for Health and Clinical Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio. NICE diagnostics guidance [DG23]. 2016.
164. Committee Opinion No. 638: First-Trimester Risk Assessment for Early-Onset Preeclampsia. Obstet Gynecol. 2015 Sep; 126(3):e25-7. https://doi.org/10.1097/AOG.0000000000001049; PMid:26287789
165. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014 Apr;4(2):105-45. https://doi.org/10.1016/j.preghy.2014.01.003; PMid:26104418
166. Tranquilli AL, Dekker G., Magee L., Roberts J., Sibai B.M., Steyn W., Zeeman G.G., Brown M.A. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97–104. https://doi.org/10.1016/j.preghy.2014.02.001; PMid:26104417
167. Рекомендации ВОЗ по профилактике и лечению преэклампсии и эклампсии / ВОЗ. – 2014. – 48c.
168. Milne F, Redman C, Walker J, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005;330(7491):576-80. https://doi.org/10.1136/bmj.330.7491.576; PMid:15760998 PMCid:PMC554032